GAITHERSBURG, Md., Sept. 8, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in two upcoming investor conferences.
H.C. Wainwright 25th Annual Global Investment Conference: | |||||
Fireside Chat | |||||
Date: | Monday, September 11, 2023 | ||||
Time: | 4:30 – 5:00 p.m. Eastern Daylight Time (EDT) | ||||
Location: | Lotte New York Palace Hotel | ||||
Moderator: | Vernon Bernardino, Managing Director, Senior | ||||
Novavax participants: | Jim Kelly, Executive Vice President, Chief Financial | ||||
Conference | |||||
Event: | Investor Meetings | ||||
Date: | Monday, September 11, 2023 | ||||
Baird 2023 Global Healthcare Conference: | |||||
Fireside Chat | |||||
Date: | Tuesday, September 12, 2023 | ||||
Time: | 10:15 – 10:45 a.m. EDT | ||||
Location: | Intercontinental New York Barclay Hotel | ||||
Moderator: | Joel L. Beatty, MD, CFA, Senior Research Analyst – | ||||
Novavax participants: | Jim Kelly, Executive Vice President, Chief Financial | ||||
Conference | |||||
Event: | Investor Meetings | ||||
Date: | Tuesday, September 12, 2023 | ||||
A replay of the recorded fireside sessions will be available through the Events and Presentations page of the Company's website at ir.novavax.com for 90 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID, influenza and COVID and influenza combined. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Ali Chartan
240-720-7804
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.20 |
| Daily Volume: | 0 |
| Market Cap: | US$993.120M |
April 15, 2025 March 11, 2025 February 27, 2025 December 13, 2024 December 10, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
